170 related articles for article (PubMed ID: 8720080)
1. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions.
Lifely MR; Hale C; Boyce S; Keen MJ; Phillips J
Glycobiology; 1995 Dec; 5(8):813-22. PubMed ID: 8720080
[TBL] [Abstract][Full Text] [Related]
2. Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose.
Sheeley DM; Merrill BM; Taylor LC
Anal Biochem; 1997 Apr; 247(1):102-10. PubMed ID: 9126378
[TBL] [Abstract][Full Text] [Related]
3. 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
James LC; Hale G; Waldmann H; Bloomer AC
J Mol Biol; 1999 Jun; 289(2):293-301. PubMed ID: 10366506
[TBL] [Abstract][Full Text] [Related]
4. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
5. A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa.
Focarelli R; Francavilla S; Francavilla F; Della Giovampaola C; Santucci A; Rosati F
Mol Hum Reprod; 1999 Jan; 5(1):46-51. PubMed ID: 10050661
[TBL] [Abstract][Full Text] [Related]
6. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
[TBL] [Abstract][Full Text] [Related]
7. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells.
Page MJ; Sydenham MA
Biotechnology (N Y); 1991 Jan; 9(1):64-8. PubMed ID: 1367214
[TBL] [Abstract][Full Text] [Related]
8. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of CAMPATH-1H: assay development and validation.
Rebello P; Hale G
J Immunol Methods; 2002 Feb; 260(1-2):285-302. PubMed ID: 11792397
[TBL] [Abstract][Full Text] [Related]
10. Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H.
Hutchins JT; Kull FC; Bynum J; Knick VC; Thurmond LM; Ray P
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):11980-4. PubMed ID: 8618827
[TBL] [Abstract][Full Text] [Related]
11. Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.
Crowe JS; Hall VS; Smith MA; Cooper HJ; Tite JP
Clin Exp Immunol; 1992 Jan; 87(1):105-10. PubMed ID: 1339322
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
Cheetham GM; Hale G; Waldmann H; Bloomer AC
J Mol Biol; 1998 Nov; 284(1):85-99. PubMed ID: 9811544
[TBL] [Abstract][Full Text] [Related]
13. Recognition of CD52 allelic gene products by CAMPATH-1H antibodies.
Hale C; Bartholomew M; Taylor V; Stables J; Topley P; Tite J
Immunology; 1996 Jun; 88(2):183-90. PubMed ID: 8690449
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of CAMPATH-1H in skeletal tumours.
Fritsche-Guenther R; Gruetzkau A; Noske A; Melcher I; Schaser KD; Schlag PM; Kasper HU; Krenn V; Sers C
Histopathology; 2010 Dec; 57(6):851-61. PubMed ID: 21166699
[TBL] [Abstract][Full Text] [Related]
16. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
[TBL] [Abstract][Full Text] [Related]
17. The glycosylation pattern of humanized IgGI antibody (D1.3) expressed in CHO cells.
Routier FH; Davies MJ; Bergemann K; Hounsell EF
Glycoconj J; 1997 Feb; 14(2):201-7. PubMed ID: 9111137
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
19. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
Taylor VC; Sims M; Brett S; Field MC
Biochem J; 1997 Mar; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
[TBL] [Abstract][Full Text] [Related]
20. Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis.
Greenwood J; Gorman SD; Routledge EG; Lloyd IS; Waldmann H
Ther Immunol; 1994 Oct; 1(5):247-55. PubMed ID: 7584499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
